A B Crujeiras1, A Díaz-Lagares, I Abete, E Goyenechea, M Amil, J A Martínez, F F Casanueva. 1. Laboratory of Molecular and Cellular Endocrinology, Instituto de Investigación Sanitaria, Complejo Hospitalario Universitario de Santiago (CHUS) and Santiago de Compostela University (USC), C/Choupana, s/n, 15706, Santiago de Compostela, Spain, anabelencrujeiras@hotmail.com.
Abstract
BACKGROUND: Leptin and ghrelin appear to play a role in weight regain after a successful weight loss. The pre-treatment plasma levels of leptin/ghrelin ratio (L/G) could have power to predict this clinically relevant issue in the obesity treatment. OBJECTIVE: To evaluate the ability of the L/G as a non-invasive tool for the early discrimination of obese patients who are more likely to regain weight after an energy restriction program (regainers) from those who maintain the lost weight (non-regainers). SUBJECTS AND METHODS: Fasting leptin and ghrelin levels were evaluated in 88 overweight/obese patients who followed an 8-week hypocaloric diet program and were categorized as regainers (≥10 % weight-lost regain) and non-regainers (<10 % weight-lost regain) 6 months (32 weeks) after finishing the dietary treatment. A receiver operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic value of the L/G ratio and to establish a cut-off point to differentiate regainers from non-regainers. RESULTS: Regainers showed a statistically higher baseline (week 0) and after treatment (week 8) L/G ratio than non-regainers. The baseline L/G ratio was associated with an increased risk for weight regain (odds ratio 1.051; p = 0.008). Using the area under the ROC curve (AUC), the L/G ratio significantly identified female (AUC = 0.69; p = 0.040) and male regainers (AUC = 0.68; p = 0.030). The maximum combination of sensitivity and specificity was shown at the cut-off point of 26.0 for women and 9.5 for men. CONCLUSIONS: The pre-intervention fasting leptin/ghrelin ratio could be a useful non-invasive approach to personalize obesity therapy and avoid unsuccessful treatment outcomes.
BACKGROUND:Leptin and ghrelin appear to play a role in weight regain after a successful weight loss. The pre-treatment plasma levels of leptin/ghrelin ratio (L/G) could have power to predict this clinically relevant issue in the obesity treatment. OBJECTIVE: To evaluate the ability of the L/G as a non-invasive tool for the early discrimination of obesepatients who are more likely to regain weight after an energy restriction program (regainers) from those who maintain the lost weight (non-regainers). SUBJECTS AND METHODS: Fasting leptin and ghrelin levels were evaluated in 88 overweight/obesepatients who followed an 8-week hypocaloric diet program and were categorized as regainers (≥10 % weight-lost regain) and non-regainers (<10 % weight-lost regain) 6 months (32 weeks) after finishing the dietary treatment. A receiver operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic value of the L/G ratio and to establish a cut-off point to differentiate regainers from non-regainers. RESULTS: Regainers showed a statistically higher baseline (week 0) and after treatment (week 8) L/G ratio than non-regainers. The baseline L/G ratio was associated with an increased risk for weight regain (odds ratio 1.051; p = 0.008). Using the area under the ROC curve (AUC), the L/G ratio significantly identified female (AUC = 0.69; p = 0.040) and male regainers (AUC = 0.68; p = 0.030). The maximum combination of sensitivity and specificity was shown at the cut-off point of 26.0 for women and 9.5 for men. CONCLUSIONS: The pre-intervention fasting leptin/ghrelin ratio could be a useful non-invasive approach to personalize obesity therapy and avoid unsuccessful treatment outcomes.
Authors: Paul S Maclean; Audrey Bergouignan; Marc-Andre Cornier; Matthew R Jackman Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-06-15 Impact factor: 3.619
Authors: Catharine M Sturgeon; Michael J Duffy; Barry R Hofmann; Rolf Lamerz; Herbert A Fritsche; Katja Gaarenstroom; Johannes Bonfrer; Thorsten H Ecke; H Barton Grossman; Peter Hayes; Ralf-Thorsten Hoffmann; Seth P Lerner; Florian Löhe; Johanna Louhimo; Ihor Sawczuk; Kazuhisa Taketa; Eleftherios P Diamandis Journal: Clin Chem Date: 2010-03-05 Impact factor: 8.327
Authors: J L Gutiérrez-Fisac; P Guallar-Castillón; L M León-Muñoz; A Graciani; J R Banegas; F Rodríguez-Artalejo Journal: Obes Rev Date: 2011-12-12 Impact factor: 9.213
Authors: Justo Sierra-Johnson; Abel Romero-Corral; Virend K Somers; Francisco Lopez-Jimenez; Anders Mälarstig; Kerstin Brismar; Anders Hamsten; Rachel M Fisher; Mai-Lis Hellénius Journal: Clin Sci (Lond) Date: 2009-03 Impact factor: 6.124
Authors: Ana B Crujeiras; Javier Campion; Angel Díaz-Lagares; Fermin I Milagro; Estíbaliz Goyenechea; Itziar Abete; Felipe F Casanueva; J Alfredo Martínez Journal: Regul Pept Date: 2013-07-05
Authors: Qi Qiao; Freek G Bouwman; Marleen A van Baak; Nadia J T Roumans; Roel G Vink; Edwin C M Mariman Journal: J Clin Endocrinol Metab Date: 2022-06-16 Impact factor: 6.134
Authors: Mary J Obayemi; Christopher O Akintayo; Adesola A Oniyide; Ayodeji Aturamu; Olabimpe C Badejogbin; Chukwubueze L Atuma; Azeezat O Saidi; Hadiza Mahmud; Kehinde S Olaniyi Journal: PLoS One Date: 2021-12-08 Impact factor: 3.240